• Business
  • Entertainment
  • Health
  • News
  • Sport
  • Tech
  • World
Newsy Today
news of today
Home - Placebo
Tag:

Placebo

Health

Fiber Blend: Relieve Constipation and Improve Stool Consistency

by Chief Editor June 30, 2026
written by Chief Editor

A combination of dietary fibers from wheat, citrus, and oats significantly improves bowel movement frequency and stool consistency in adults with chronic functional constipation, according to a randomized clinical trial published in the journal Food Science & Nutrition. Researchers found that a daily 13-gram supplement dose containing resistant dextrin, pectins, and insoluble fiber provided faster relief than placebo without the typical gastrointestinal discomfort associated with single-source fiber supplements.

How does a multi-fiber blend treat constipation?

The study suggests that mixing different fiber sources creates a complementary mechanism that addresses constipation more effectively than isolated fiber types. According to the study, the supplement used a blend of resistant dextrin from wheat starch, pectins, insoluble citrus fiber, and oat fiber containing β-glucan. This combination targets the gut through two distinct pathways: fermentation and mechanical stimulation.

In the colon, gut microbes ferment these fibers to produce bioactive compounds, while the insoluble components absorb water to increase stool bulk. This mechanical action triggers the intestinal mucosa to secrete mucus, which improves motility. By using a blend, researchers report they achieved clinical benefits at a lower dosage than what is typically required when using resistant dextrin alone, effectively minimizing side effects like bloating.

Did you know?
Up to 15% of the population suffers from chronic constipation. This condition is defined by fewer than three bowel movements per week, persistent straining, or a feeling of incomplete evacuation lasting for three or more months.

What were the results of the clinical trial?

The randomized, double-blind, placebo-controlled trial followed 54 Caucasian adults over 28 days. Participants taking the fiber supplement showed a progressive increase in spontaneous, complete bowel movements compared to the control group. By the end of the second week, the treatment group reported one additional bowel movement per week, growing to two additional movements by the end of the follow-up period.

What were the results of the clinical trial?

Stool consistency, measured by the Bristol Stool Form Scale (BSFS), also showed significant improvement. The study notes that the greatest difference in consistency scores between the treatment and placebo groups occurred at the end of week four. Furthermore, participants reported a reduction in secondary symptoms, including abdominal bloating, heaviness, and flatulence. The supplement was well-tolerated, and no participants required rescue laxatives during the trial period.

What are the limitations of these findings?

While the results show promise, the study authors emphasize that the findings have limitations that warrant further research. The small sample size of 54 participants and the single-center design mean the results may not be generalizable to broader, more diverse populations. Because all participants were Caucasian, future studies are needed to determine if these benefits persist across different ethnic groups.

Researchers study the impact of whole food dietary fiber on gut health

The trial also relied on participant-reported symptom diaries, which are inherently subjective. Additionally, the one-week follow-up period was too short to determine the long-term sustainability of the treatment. Researchers suggest that larger, multicenter studies are required to validate these findings and to explore potential shifts in the gut microbiota resulting from long-term fiber supplementation.

Pro Tip: Managing Fiber Intake

If you are looking to increase fiber intake, do so gradually. Rapidly increasing fiber can lead to temporary gas or abdominal distension. Always pair increased fiber consumption with adequate hydration to ensure the fiber can move effectively through the digestive tract.

Frequently Asked Questions

Why is chronic constipation difficult to treat?

Chronic constipation is often resistant to conventional treatments because patients frequently fail to consume enough vegetables and whole grains. Additionally, high doses of single-source fibers can sometimes trigger side effects like bloating and gas, leading patients to discontinue use.

Frequently Asked Questions

How does this fiber blend differ from over-the-counter laxatives?

Unlike many laxatives that can cause urgent or uncomfortable bowel movements, this fiber blend works by utilizing the gut’s natural mechanisms. By combining soluble and insoluble fibers, the supplement modulates gut microbiota and increases stool bulk simultaneously, offering a more balanced approach to bowel health.

Is this fiber supplement safe for everyone?

While the study reported no adverse events among the 54 participants, it is essential to consult with a healthcare provider before starting any new supplement regimen, especially for those with underlying digestive conditions or specific dietary restrictions.


Have you struggled with finding an effective way to manage digestive health? Share your experiences in the comments below or subscribe to our newsletter for the latest updates on nutritional science and digestive health research.

June 30, 2026 0 comments
0 FacebookTwitterPinterestEmail
Health

High-Dose DHA Fails to Boost Memory Despite Brain Penetration

by Chief Editor June 25, 2026
written by Chief Editor

High-dose docosahexaenoic acid (DHA) supplementation successfully increases omega-3 levels in the human brain but fails to halt cognitive decline or structural brain changes, according to a randomized clinical trial published in eBioMedicine. Researchers monitored 365 older adults over two years, finding that while the supplement reached the central nervous system, it provided no measurable benefit to memory or brain health, regardless of a participant’s APOE ε4 genetic risk status.

Why does brain DHA delivery fail to stop cognitive decline?

The study confirms that the “delivery problem”—the assumption that DHA simply isn’t reaching the brain in sufficient quantities—is likely incorrect. According to the eBioMedicine findings, participants receiving 2 grams of DHA daily saw their cerebrospinal fluid (CSF) DHA levels rise by 17% within six months. Despite this, there was no significant difference in brain volume or cognitive performance compared to the placebo group after 24 months.

This suggests that the bottleneck isn’t getting the nutrient into the brain, but rather how the brain metabolizes it. The study authors suggest that enzymatic catabolism within synaptic membranes may break down DHA before it can exert a neuroprotective effect. This finding contrasts with earlier observational studies that linked higher dietary omega-3 intake to lower dementia risk, highlighting a gap between correlation and clinical intervention.

Did you know?

The APOE ε4 gene variant is the most significant genetic risk factor for Alzheimer’s disease. While this study found that APOE ε4 carriers showed lower cognitive improvement than non-carriers, both groups experienced successful DHA delivery to the brain, proving the gene does not block the nutrient’s entry.

What is the future of Alzheimer’s prevention research?

Because simply increasing intake does not equate to better brain function, the focus of Alzheimer’s research is shifting from broad supplementation to targeted metabolic regulation. Future trials are expected to move away from testing DHA as a standalone “magic bullet.” Instead, scientists are looking toward personalized approaches that address multiple risk factors simultaneously, such as hypertension, vascular health, and inflammation.

According to the researchers, future studies should focus on how DHA is processed within individual brain cells. This may involve using more granular neuropsychological testing or advanced imaging markers to detect subtle signs of neurodegeneration before clinical symptoms appear. Researchers suggest that testing in individuals already showing early biochemical markers—such as phosphorylated tau in the blood—may be the next necessary step to determine if DHA has any therapeutic window.

How did the study design impact the results?

The trial faced a significant challenge with a 38% dropout rate, largely attributed to the COVID-19 pandemic. According to the study data, those who left the trial were more likely to have lower baseline education levels and lower plasma DHA concentrations. This attrition may have skewed the final results toward a more highly educated, healthier participant pool, potentially masking smaller therapeutic effects.

Pro Tip: When evaluating nutritional supplements for cognitive health, consider that systemic health factors—like physical inactivity and cardiovascular disease—often play a larger role in brain aging than any single nutrient. Always consult with a neurologist before starting high-dose regimens.

Frequently Asked Questions

Does taking DHA supplements prevent Alzheimer’s?

Current clinical evidence, including the recent eBioMedicine trial, indicates that high-dose DHA supplementation does not prevent cognitive decline or improve brain structure in older adults, even when the DHA successfully reaches the brain.

Frequently Asked Questions

Is DHA still important for brain health?

Yes. DHA remains a critical fatty acid for synaptic function and neuroinflammation modulation. However, this study suggests that “more” is not necessarily “better” once a certain threshold of brain uptake is reached.

Did the APOE ε4 gene affect how DHA reached the brain?

No. The study found that DHA delivery to the brain was independent of APOE ε4 status. Carriers and non-carriers both saw increases in CSF DHA levels.


Are you interested in the latest developments in neurodegenerative research? Subscribe to our newsletter for expert-led updates on clinical trials and brain health science.

June 25, 2026 0 comments
0 FacebookTwitterPinterestEmail
Health

Do Fish Oil Supplements Prevent Alzheimer’s?

by Chief Editor June 19, 2026
written by Chief Editor

High-dose fish oil supplements do not improve memory or prevent brain cell loss in older adults at risk for Alzheimer’s disease, according to a study published in eBioMedicine by researchers at Keck Medicine of USC. Despite evidence that the omega-3 fatty acid DHA successfully reaches the brain, the two-year clinical trial found no significant cognitive benefits compared to a placebo.

Why don’t omega-3 supplements protect the brain?

While omega-3 fatty acids are essential for building brain cell connections, their presence in the brain does not automatically translate to improved cognitive health. According to Dr. Hussein Naji Yassine, director of the USC Center for Personalized Brain Health, the study confirmed an average 17% increase in DHA levels in the cerebrospinal fluid of participants, proving the supplement reached its target. However, this physiological uptake failed to prevent the shrinkage of the hippocampus—a key marker of brain aging—or improve performance on memory and cognitive tests.

Did you know?
Americans spend over $1 billion annually on fish oil supplements, largely driven by the belief that they act as a preventative measure for cognitive decline.

How did the USC clinical trial work?

Researchers recruited 365 adults between the ages of 55 and 80 who had low baseline fish intake and were considered at risk for Alzheimer’s. Approximately 47% of the participants carried the APOE4 gene, which is the strongest genetic risk factor for late-onset Alzheimer’s. Participants were randomly assigned to receive either a daily dose of 2,000 mg of DHA or a placebo. After two years of monitoring, the study concluded that those taking the high-dose supplements performed no better on cognitive assessments than the control group.

How did the USC clinical trial work?

Are supplements less effective than a balanced diet?

The research team suggests that omega-3s may be more effective when consumed as part of a Mediterranean-style diet rather than through isolated supplements. Previous observational studies have linked diets naturally rich in omega-3s to lower Alzheimer’s risk, but this trial highlights a discrepancy: the isolated nutrient does not appear to provide the same protective effect. Dr. Yassine noted that the team is now investigating how factors like age, genetic risk, and overall dietary patterns influence the brain’s ability to utilize these nutrients effectively.

Pro Tips for Brain Health

  • Prioritize Whole Foods: Focus on a Mediterranean-style diet rather than relying on pills to meet nutritional needs.
  • Maintain Routine Maintenance: Dr. Yassine compares the brain to a car engine; regular exercise, quality sleep, and a balanced diet are required to keep it running smoothly.
  • Address Systemic Health: Untreated health issues in other parts of the body can accelerate brain function loss.

Frequently Asked Questions

Do fish oil supplements reach the brain?

Yes. According to the USC study, 2,000 mg of daily DHA resulted in a 17% increase of the nutrient in the cerebrospinal fluid after six months.

#147-Hussein Yassine, M.D.: Deep dive into the “Alzheimer’s gene” (APOE), brain health, and omega-3s

Does taking omega-3s prevent Alzheimer’s?

The findings from this study do not support the use of fish oil supplements as a preventive measure against Alzheimer’s, as they did not improve cognitive function or prevent hippocampal shrinkage.

What is the best way to support cognitive health?

Researchers recommend a holistic approach, including regular exercise, quality sleep, and a nutrient-dense, balanced diet.


Are you concerned about cognitive health and looking for evidence-based strategies? Subscribe to our newsletter for the latest updates on brain health research and clinical trials, or explore our archives for more expert-led health insights.

June 19, 2026 0 comments
0 FacebookTwitterPinterestEmail
Health

Diabetes Drug Significantly Reduces Heart Failure Risk in Genetic Carriers

by Chief Editor June 8, 2026
written by Chief Editor

New research published in Nature Medicine reveals that the medication dapagliflozin significantly reduces the risk of heart failure in patients who carry specific cardiomyopathy-associated genetic variants. Findings from the Mass General Brigham Heart and Vascular Institute and the Broad Institute of MIT and Harvard suggest that these genetic markers could help clinicians identify patients who derive a substantially larger benefit from the drug than the general population.

Why Genetic Screening Matters for Heart Failure Prevention

Historically, identifying a genetic variant linked to cardiomyopathy primarily served to inform patients of their elevated risk, often without a targeted preventative strategy. According to Dr. Shinwan Kany, a visiting scientist at the Cardiovascular Research Center, this new data demonstrates that specific tools, such as dapagliflozin, can effectively lower that risk.

Why Genetic Screening Matters for Heart Failure Prevention

The research, led by scientists at Mass General Brigham and the Broad Institute, highlights a shift toward genetically guided interventions. Dr. Christian T. Ruff, a cardiologist at Mass General Brigham and Senior Investigator at the TIMI Study Group, notes that this approach could protect vulnerable patients long before they begin to show outward symptoms of heart disease.

Did you know?
Dapagliflozin works by increasing the excretion of glucose and sodium in the urine. This process is thought to help the heart function more efficiently, which is why it is used to treat both type 2 diabetes and heart failure.

How Much Does Dapagliflozin Reduce Risk?

The study analyzed data from the DECLARE-TIMI 58 trial, a phase 3 clinical trial involving 12,685 participants with type 2 diabetes. Among this group, researchers identified 121 individuals carrying a cardiomyopathy variant. During a median follow-up of 4.2 years, the drug demonstrated a clear protective impact:

Dr. Scott Solomon: Dapagliflozin Benefits Patients With Heart Failure and Kidney Disease
  • Non-carriers: Dapagliflozin reduced heart failure hospitalizations by 32% compared to a placebo.
  • Variant carriers: The drug reduced the risk of heart failure hospitalizations by approximately 80% compared to those who received a placebo.

Specifically, 16% of carriers in the placebo group were hospitalized for heart failure, compared to only 3% in the group treated with dapagliflozin. According to the study published in Nature Medicine, these protective effects were observed in participants regardless of their prior history of heart failure.

What Happens Next for Patients?

Dr. Nicholas A. Marston, a cardiologist with the Mass General Brigham Heart and Vascular Institute, emphasizes that cardiomyopathy variants represent an “actionable genotype.” This is particularly relevant for patients who have not yet developed established heart failure, a group for whom doctors might not otherwise initiate this specific treatment.

What Happens Next for Patients?

Because the trial focused exclusively on patients with type 2 diabetes, the researchers state that more study is required. Future investigations will need to determine if dapagliflozin offers the same level of protection for cardiomyopathy variant carriers who do not have diabetes.

Frequently Asked Questions

What is dapagliflozin?
Dapagliflozin is an SGLT2 inhibitor primarily used to treat type 2 diabetes. It is also used to treat adults with heart failure and chronic kidney disease, according to the NHS and Drugs.com.

Can genetic testing change heart failure treatment?
Yes. According to researchers at Mass General Brigham, identifying cardiomyopathy-associated genetic variants can help clinicians pinpoint which patients are likely to see the greatest benefit from preventative treatments like dapagliflozin.

Does dapagliflozin treat type 1 diabetes?
No. The Mayo Clinic notes that dapagliflozin is not intended for patients with insulin-dependent or type 1 diabetes.

Pro Tip:
Always consult with your cardiologist or primary care provider regarding genetic screening. Understanding your unique genetic profile can help your medical team personalize your long-term heart health strategy.

Are you interested in learning more about how genetics are changing modern medicine? Subscribe to our newsletter for the latest updates on clinical research and heart health breakthroughs.

June 8, 2026 0 comments
0 FacebookTwitterPinterestEmail
Health

How Histamine Boosts Memory, Decisions, and Learning

by Chief Editor June 4, 2026
written by Chief Editor

Beyond Dopamine: Why Histamine is the Next Frontier in Cognitive Enhancement

For decades, the conversation around brain health and “smart drugs” has been dominated by two heavyweights: dopamine and serotonin. We talk about dopamine for motivation and serotonin for mood. But a groundbreaking shift is occurring in neurobiology, and it’s centering on a much older, long-neglected player: histamine.

Recent research published in Nature Communications has revealed that histamine isn’t just about allergies or sleep-wake cycles. This proves a fundamental architect of how we learn, remember, and make decisions. As we look toward the next decade of neuroscience, the ability to fine-tune histaminergic signaling could redefine everything from how we treat Alzheimer’s to how we optimize human performance.

Did you know? Histamine was actually the very first monoamine neurotransmitter discovered in the mammalian brain, yet it has remained in the shadow of dopamine for nearly a century.

The Rise of “Precision Cognition”

The traditional approach to cognitive enhancement has often been a “blunt instrument” approach—using stimulants that increase general arousal but often lead to jitteriness or anxiety. The future, however, lies in precision cognition.

The recent study utilized pitolisant, an H3 receptor inverse agonist, to show that You can specifically target the brain’s ability to consolidate memories. By increasing histamine signaling, researchers observed enhanced connectivity between the hippocampus and the mammillary zone—the brain’s “filing cabinet” for long-term storage.

This suggests a future where “smart” therapeutics don’t just make you feel “wired,” but actually improve the efficiency of your neural networks. We are moving toward a world where we can theoretically “dial in” specific cognitive functions, such as working memory or rapid information processing, without the systemic side effects of traditional stimulants.

Stabilizing the Mind: A New Tool for Mental Health

Perhaps the most profound implication of this research isn’t about getting “smarter”—it’s about becoming more emotionally resilient. One of the most startling findings in the study was histamine’s effect on reinforcement learning.

In the trial, participants with elevated histamine levels showed a reduced learning rate when processing “aversive” or negative outcomes. While that sounds counterintuitive, it is actually a massive advantage for psychological stability. In a stable environment, being overly reactive to every single negative event can lead to anxiety and erratic decision-making.

The End of Over-Reactivity?

Imagine a future where neuro-therapies can help individuals manage PTSD or chronic anxiety by modulating how the brain “updates” its value system after a negative experience. By stabilizing the way we learn from loss, histamine-based treatments could prevent the brain from becoming “stuck” in a cycle of fear-based learning.

Histamine and ADHD: How This Key Neurotransmitter Influences Brain Function, Focus, Memory and Mood

This moves us into the realm of computational psychiatry, where we treat mental health disorders not just as “chemical imbalances,” but as errors in the neurocomputational dynamics of the brain.

Pro Tip: While pharmacological research is advancing, maintaining healthy sleep hygiene is the most natural way to support your histaminergic system, as histamine plays a critical role in regulating your circadian rhythm.

Future Trends: What to Watch For

As this field matures, keep an eye on these three emerging trends:

  • Nootropic 2.0: A shift away from caffeine and toward highly specific H3 and H4 receptor modulators designed for deep work and memory retention.
  • Neurodegenerative Defense: Using histamine signaling to bolster the hippocampus in the early stages of Alzheimer’s and other dementias.
  • AI-Driven Neuro-Mapping: Using machine learning (similar to the techniques used in the recent study) to predict exactly how a specific individual’s brain will respond to histamine modulation.

The implications are clear: the “forgotten” neurotransmitter may hold the key to unlocking a more stable, efficient, and resilient human mind.


Frequently Asked Questions

Is histamine the same thing as an allergy?

While histamine is the primary chemical responsible for allergic reactions, in the brain, it acts as a vital neurotransmitter that regulates alertness, memory, and learning.

Is histamine the same thing as an allergy?
Juan Gaertner histamine research

Can I take histamine-boosting supplements for memory?

Current research is focused on pharmaceutical-grade H3 receptor modulators like pitolisant. Always consult a medical professional before attempting to alter neurotransmitter levels through supplements, as the balance is delicate.

How does histamine affect decision-making?

According to recent studies, histamine helps the brain accumulate “evidence” more efficiently, allowing for faster and more accurate recognition of information and more stable learning from both positive and negative experiences.

Will these drugs be available for healthy adults soon?

Most current research is focused on clinical applications (such as narcolepsy or cognitive impairment). However, the “cognitive enhancement” market often follows clinical breakthroughs, so the potential for healthy use remains a significant area of interest.

Stay Ahead of the Science

The frontier of neuroscience is moving faster than ever. Don’t get left behind.

Want more deep dives into the future of brain health?

Subscribe to Our Newsletter

Join 50,000+ readers receiving weekly insights into neuro-tech and longevity.

June 4, 2026 0 comments
0 FacebookTwitterPinterestEmail
Health

Early Paracetamol Speeds Up PDA Closure in Preterm Infants

by Chief Editor June 3, 2026
written by Chief Editor

A Breakthrough in Neonatal Care: Could Paracetamol Be the Future for Preterm Infants?

For parents and medical professionals, the arrival of an extremely preterm baby is a high-stakes race against time. Among the most common complications in infants born before 28 weeks is a condition called Patent Ductus Arteriosus (PDA). This occurs when a vital fetal blood vessel fails to close after birth, potentially leading to life-threatening heart and lung complications.

Recent research from the University of Oulu and Oulu University Hospital has ignited a conversation that could redefine neonatal intensive care unit (NICU) protocols globally. The study suggests that early, low-dose administration of paracetamol might be a game-changer in helping these tiny hearts function as they should.

The Science Behind the PDA Challenge

The ductus arteriosus is a normal structure in the womb that allows blood to bypass the non-functioning fetal lungs. In a full-term pregnancy, this vessel usually closes naturally within hours or days of birth. However, for the most vulnerable “micro-preemies,” this natural closure is often delayed or fails entirely.

Traditionally, doctors have relied on specific anti-inflammatory medications or even surgical intervention to force closure. But these treatments aren’t without risks, including potential side effects on kidney function or the gastrointestinal tract. This is why the prospect of a gentler, more effective intervention like paracetamol has the medical community buzzing.

Did you know?

A “micro-preemie” is defined as an infant born before 28 weeks of gestation or weighing less than 1,000 grams (about 2.2 pounds). Managing their care requires extreme precision, as their organs are still in the early stages of development.

Key Findings: Faster Closure, Fewer Risks

In a randomized, double-blind trial, researchers observed a stark difference between infants treated with paracetamol and those given a placebo. The median time to ductal closure was just three days for the paracetamol group, compared to 14 days for those who received the placebo.

Even more encouraging was the safety profile. The study reported no significant increase in adverse events among the infants receiving the medication. With a 75% closure rate in the treated group versus 35% in the control group, the data suggests that we may be looking at a future standard of care that is both proactive and well-tolerated.

What This Means for NICU Protocols

While these results are promising, medical experts caution against premature changes to clinical guidelines. “This was a pilot study,” notes lead researcher T. Ukkonen. “While the efficacy is clear, we need larger-scale, multi-center trials to ensure this approach is safe for every demographic of preterm infant before it becomes a worldwide standard.”

Studying at the Faculty of Medicine of the University of Oulu
Pro Tip: Understanding Neonatal Research

When reading about new medical trials, always look for the sample size. Small pilot studies are essential for testing hypotheses, but they serve as a “proof of concept” rather than a final mandate for clinical practice.

Looking Ahead: The Future of Neonatal Medicine

The shift toward “prophylactic” or preventive medicine in the NICU is a major trend. Instead of waiting for a complication like PDA to become severe, clinicians are increasingly looking for ways to support the infant’s natural development from the moment of birth.

As genomic medicine and personalized neonatal care continue to evolve, we can expect:

  • Earlier Intervention: Moving away from “wait and see” approaches toward evidence-based early support.
  • Drug Repurposing: Using well-understood, safe medications like paracetamol for new, specialized applications.
  • Enhanced Monitoring: Utilizing advanced echocardiography to track minute changes in cardiac function in real-time.

Frequently Asked Questions (FAQ)

What is Patent Ductus Arteriosus (PDA)?
It is a condition where a fetal blood vessel fails to close after birth, causing blood to flow abnormally between the heart, and lungs.
Why is this new study significant?
It suggests that a simple, common medication could safely accelerate the closure of the ductus, potentially reducing the need for more invasive treatments or surgeries.
Is paracetamol now the standard treatment for all preterm babies?
Not yet. While the pilot study results are highly positive, researchers emphasize that larger clinical trials are required before this becomes a standard part of hospital guidelines.

Have questions about the latest advancements in neonatal care or want to share your experience? Leave a comment below, or subscribe to our health newsletter to stay updated on the latest medical breakthroughs.

June 3, 2026 0 comments
0 FacebookTwitterPinterestEmail
Health

New Oral Drug Boosts Platelet Recovery in GI Cancer Patients

by Chief Editor May 22, 2026
written by Chief Editor

Breaking Barriers in Cancer Care: Oral Medication Shows Promise for Chemotherapy Side Effects

For patients battling gastrointestinal cancers, the journey through chemotherapy is often interrupted by a common but debilitating obstacle: chemotherapy-induced thrombocytopenia (CIT). This condition, characterized by low blood platelet counts, often forces clinicians to delay or reduce life-saving treatment doses, which can negatively impact overall patient outcomes.

However, recent results from a phase 2 clinical trial offer a glimpse of a more seamless future for cancer treatment. Researchers at the Sylvester Comprehensive Cancer Center, part of the University of Miami Miller School of Medicine, and Mass General Hospital have identified that an oral medication, avatrombopag, may provide a significant breakthrough for those struggling to maintain the platelet counts necessary to stay on schedule with their chemotherapy.

Did you know?

Platelets are vital blood cells that help the body form clots. When counts drop too low due to chemotherapy, patients face a heightened risk of life-threatening bleeding even from minor injuries.

The Power of Oral Treatment Options

Avatrombopag is a thrombopoietin receptor agonist already approved for use in patients with liver disease. In the recent clinical trial, the drug demonstrated remarkable efficacy in helping patients with gastrointestinal cancers recover their platelet levels. Among the trial participants, 65% of those receiving avatrombopag met key treatment goals, compared to just 17% of those in the placebo group.

Gerald A. Soff, M.D., chief of classical hematology at Sylvester, who led the trial, emphasized the importance of these findings. “These are the patients, based on our experience, who have the greatest need and will benefit the most from use of a thrombopoietin receptor agonist,” Soff noted.

One of the most significant advantages of this medication is its oral administration. Currently, many treatments for CIT require frequent trips to an infusion center for injections. For patients already dealing with the physical and emotional burden of metastatic cancer, eliminating the need for weekly travel can significantly improve their quality of life.

“You can imagine if someone is dealing with metastatic cancer and they’re not feeling great, and they’re trying to maintain a life, having to go in every single week for a shot is not ideal,” Soff said. “If there’s a good oral option, that would be very appealing for many people.”

Why Consistency in Chemotherapy Matters

The primary goal of this therapy is to avoid compromising cancer treatment. When platelet counts remain high, patients can receive their chemotherapy as originally scheduled. According to Soff, there is clear evidence that dose reductions or delays can impact cancer outcomes. By stabilizing platelet counts, clinicians hope to keep patients on their intended treatment trajectory without interruption.

Why Consistency in Chemotherapy Matters
Cancer Patients Soff
Pro Tip:

If you or a loved one are experiencing treatment delays due to low blood counts, discuss the latest clinical trial developments with your oncologist. Asking about emerging oral options can be a proactive way to manage your care plan.

Looking Ahead: The Future of CIT Management

While the initial study focused on patients with gastrointestinal cancers to ensure consistent data, researchers believe the benefits could extend to many other tumor types. The trial was so effective that researchers were able to complete their analysis at 23 patients, rather than the original goal of 40. Moving forward, the team is continuing to monitor these patients to understand the long-term benefits of the medication.

Prof Gerald A Soff | Role of Romiplostim in Chemotherapy induced Thrombocytopenia

As the medical community continues to explore thrombopoietin receptor agonists, the shift toward convenient, patient-friendly oral treatments represents a major step forward in supportive oncology care.

Frequently Asked Questions

What is chemotherapy-induced thrombocytopenia (CIT)?

CIT is a common side effect of chemotherapy where the body’s blood platelet count drops, making it challenging for the blood to clot properly and often requiring a delay in cancer treatment.

What is chemotherapy-induced thrombocytopenia (CIT)?
Cancer Patients

Why is an oral medication preferred over injections?

Oral medications allow patients to manage their condition at home, reducing the need for frequent, often difficult travel to clinics or infusion centers for injections.

Is avatrombopag currently approved for CIT?

While avatrombopag is FDA-approved for thrombocytopenia in patients with liver disease, it is not yet approved for CIT. However, recent clinical trials have shown significant promise for this use.


Are you interested in learning more about the latest breakthroughs in cancer supportive care? Subscribe to our newsletter for the latest updates or explore our oncology archives to read more about innovative clinical trials.

May 22, 2026 0 comments
0 FacebookTwitterPinterestEmail
Health

Daily orforglipron treatment reduces weight and blood sugar in seniors

by Chief Editor May 11, 2026
written by Chief Editor

The Shift Toward Oral Metabolic Health: A New Era for Seniors

For years, the conversation around weight management in older adults has been cautious. The fear of muscle loss, the complexity of injectable medications, and a general lack of clinical data specifically targeting the 65+ demographic often left healthcare providers and patients hesitant. However, a significant shift is underway as the industry moves toward oral, non-peptide GLP-1 receptor agonists.

The emergence of medications like orforglipron—developed by Eli Lilly and approved by the FDA for chronic weight management—represents more than just a change in delivery method. It signals a future where metabolic health is tailored to the physiological needs of aging adults, removing the “needle barrier” and expanding access to life-changing therapy.

Did you know? Unlike many previous GLP-1 medications that require injections, orforglipron is a small-molecule, non-peptide oral medication, making it significantly easier for patients to integrate into a daily routine.

Breaking the Age Barrier in Obesity Treatment

One of the most persistent myths in geriatric care is that weight loss in seniors is either too risky or less effective. Recent post-hoc analyses from the ATTAIN clinical trial programme are dismantling this narrative. Data indicates that adults aged 65 and older experience weight reduction and blood sugar improvements similar to those seen in younger populations.

In the ATTAIN-1 trial, which focused on participants with obesity but without type 2 diabetes (T2D), those aged 65+ saw statistically significant weight loss at week 72: 7.9% for the 6 mg dose, 11.3% for the 12 mg dose, and 13.0% for the 36 mg dose, compared to just 1.6% for the placebo group.

The results were mirrored in the ATTAIN-2 trial for those with both obesity and T2D, where the 36 mg dose led to a 12.2% weight reduction. This suggests that the biological mechanisms of GLP-1 receptor agonists remain highly effective regardless of age.

Beyond the Scale: Managing Comorbidities

Future trends in obesity medicine are moving away from “weight loss for aesthetics” and toward “metabolic optimization.” For older adults, this means addressing the cluster of conditions that often accompany obesity, such as hypertension and type 2 diabetes.

The data highlights the critical intersection of these conditions; in the ATTAIN trials, a staggering 79.1% of participants in ATTAIN-1 and 86.2% in ATTAIN-2 had hypertension as a comorbidity. The ability of oral GLP-1s to simultaneously tackle multiple health markers is a game-changer for geriatric medicine.

The Impact on Blood Sugar and Quality of Life

For those battling T2D, the benefits extend far beyond the scale. Participants in the studies saw meaningful reductions in glycated haemoglobin (HbA1c), with the 36 mg dose resulting in a 1.7% reduction compared to 0.1% for the placebo. Beyond these metrics, improvements were noted in:

The Impact on Blood Sugar and Quality of Life
Beyond
  • BMI and waist circumference
  • Triglycerides and non-HDL cholesterol
  • Overall health-related quality of life
Pro Tip: When discussing GLP-1 therapies with a provider, seniors should prioritize a comprehensive review of their current medications. Because these drugs affect metabolic markers, monitoring for interactions with blood pressure or diabetes medications is essential.

Safety, Sustainability, and the “Muscle Concern”

A primary concern for clinicians treating older adults is the risk of lean muscle mass loss, which can lead to frailty or an increased risk of fractures. However, evidence suggests that these risks are manageable. In the ATTAIN analysis, there was no statistically significant difference in treatment-emergent adverse events related to muscle mass loss, such as fractures, between the orforglipron group (6.6%) and the placebo group (4.3%).

Safety, Sustainability, and the "Muscle Concern"
Muscle Concern

Similarly, renal events and major adverse cardiovascular events showed no significant disparity between the treatment and placebo groups. While gastrointestinal issues remain the most common side effect—affecting 64.7% of users compared to 37.5% for placebo—these were mostly reported as mild or moderate in severity.

As Dr. Deborah Horn, Director of the Center for Obesity Medicine and Metabolic Performance at McGovern Medical School at UTHealth Houston, notes: “Age should not be a barrier to considering orforglipron.”

Frequently Asked Questions

Is orforglipron safe for people over 65?
Yes. Clinical data from the ATTAIN trials indicate that the safety profile for adults 65 and older is generally consistent with the broader population, with no significant increase in fractures or major cardiovascular events.

How does the oral version differ from injectable GLP-1s?
Orforglipron is a non-peptide, small-molecule medication taken once daily by mouth, eliminating the need for injections and potentially improving patient adherence.

What are the most common side effects for seniors?
The most common adverse events are gastrointestinal in nature. While more frequent in the treatment group than the placebo group, they are typically mild to moderate.

Can it be used if I have type 2 diabetes?
Yes. The medication has shown significant efficacy in reducing both body weight and HbA1c levels in adults with obesity and type 2 diabetes.

Want to stay updated on the latest breakthroughs in metabolic health? Subscribe to our newsletter or explore our guide to GLP-1 medications to learn more about how these therapies are reshaping modern medicine. Share your thoughts or questions in the comments below!

May 11, 2026 0 comments
0 FacebookTwitterPinterestEmail
Health

Alzheimer’s monoclonal antibodies fail to deliver meaningful results

by Chief Editor April 21, 2026
written by Chief Editor

The Amyloid Paradox: Clearing Plaques vs. Restoring Memory

For years, the scientific community focused on the “amyloid hypothesis”—the idea that removing amyloid-beta (Aβ) plaques from the brain would stop or reverse Alzheimer’s disease. Recent data shows a complex reality: while monoclonal antibodies (mAbs) are highly effective at clearing these plaques, the clinical results are a subject of intense debate.

View this post on Instagram about Alzheimer, Amyloid
From Instagram — related to Alzheimer, Amyloid

A systematic review of 17 randomized controlled trials involving 20,342 participants indicates that these therapies may result in little to no meaningful difference in cognitive function or dementia severity at the 18-month mark. This gap between biological success (plaque removal) and clinical success (cognitive improvement) suggests that clearing amyloid may not be the “silver bullet” once imagined.

Did you realize? Monoclonal antibodies work by activating microglia—the brain’s immune cells—to engulf and clear fibrillar amyloid-beta protein plaques.

Shifting the Focus: The Move Toward Alternative Mechanisms

Since successful amyloid clearance does not always translate into meaningful clinical improvement, the future of Alzheimer’s treatment is likely to diversify. Experts are now calling for research into alternative therapeutic mechanisms of action.

While the first wave of disease-modifying therapies targeted Aβ, the next frontier involves addressing the broader pathology of the disease. This includes looking beyond plaques to intracellular neurofibrillary tangles of hyperphosphorylated tau protein, which also contribute to neuronal loss and synaptic dysfunction.

The Role of Combination Therapies

Rather than relying on a single target, future trends point toward “cocktail” approaches. By combining amyloid-lowering agents with therapies that target tau or other neurodegenerative processes, clinicians hope to achieve a more significant slowing of cognitive decline.

The “Biological Continuum” Approach: Early Intervention

One of the most significant shifts in Alzheimer’s management is the conceptualization of the disease as a biological continuum. This means AD is no longer seen as something that begins with memory loss, but as a process that starts in an asymptomatic preclinical stage.

What patients need to know about antiamyloid monoclonal antibodies for Alzheimer’s disease

Recent progress suggests that treating patients earlier in this continuum—during the mild cognitive impairment (MCI) stage—may be more effective. Some newer therapies, such as lecanemab and donanemab, have shown more promising results in reducing plaques and slowing decline when administered in these early stages.

Pro Tip: Early detection is becoming more feasible thanks to novel biomarkers that measure amyloid-β and phosphorylated tau (P-tau), allowing for a biomarker-supported diagnosis before severe dementia sets in.

Precision Medicine and the Challenge of Safety

As we move toward a more personalized approach to Alzheimer’s, managing the risks associated with these powerful drugs is paramount. The most notable safety concern is Amyloid-Related Imaging Abnormalities (ARIA), which can appear as edema (ARIA-E) or microhemorrhages (ARIA-H) on an MRI.

Precision Medicine and the Challenge of Safety
Alzheimer Amyloid Related Imaging Abnormalities

The future of these treatments will depend on “precision prescribing”—using genetic and biomarker data to identify which patients are most likely to benefit from drugs like aducanumab or lecanemab while minimizing the risk of serious adverse events.

Current evidence highlights a persistent tradeoff: while some patients may see a slight slowing of functional decline, the risk of ARIA remains a critical consideration for clinicians and patients alike.

FAQ: Understanding Anti-Amyloid Therapies

Do anti-amyloid antibodies cure Alzheimer’s?

No. They are described as disease-modifying therapies that aim to sluggish cognitive and clinical decline rather than provide a cure.

What is ARIA?

ARIA stands for Amyloid-Related Imaging Abnormalities. It refers to brain swelling (edema) or small bleeds (hemorrhages) that can be detected via MRI during treatment with monoclonal antibodies.

Who are these treatments intended for?

These therapies are generally intended for patients in the early stages of the disease, such as those with mild cognitive impairment (MCI) or mild Alzheimer’s dementia who have proven amyloid pathology.

Why is plaque removal not enough?

Evidence suggests that while antibodies can successfully clear amyloid-beta plaques, this biological change does not always lead to a clinically meaningful improvement in memory or daily functioning.

Want to stay updated on the latest breakthroughs in neurodegenerative research? Subscribe to our health insights newsletter or leave a comment below to share your thoughts on the future of Alzheimer’s care.

April 21, 2026 0 comments
0 FacebookTwitterPinterestEmail
Health

Evolocumab reduces cardiac events in high-risk diabetic patients

by Chief Editor March 30, 2026
written by Chief Editor

Evolocumab: A New Era in Proactive Heart Disease Prevention?

A groundbreaking analysis from the VESALIUS-CV trial, presented at the American College of Cardiology’s Annual Scientific Session, suggests a potential shift in how we approach heart disease prevention. The study reveals that evolocumab, a PCSK9 inhibitor, significantly reduced the risk of major cardiovascular events – by nearly one-third – in patients with diabetes without known significant atherosclerosis. This challenges the long-held belief that these powerful cholesterol-lowering drugs should be reserved for those who have already experienced a heart attack or stroke.

Beyond Secondary Prevention: Targeting Risk Earlier

For years, PCSK9 inhibitors like evolocumab have been a cornerstone of secondary prevention, helping patients who’ve already suffered a cardiac event avoid future problems. VESALIUS-CV is the first major trial to demonstrate a benefit in high-risk primary prevention – meaning preventing a first event in individuals without a prior history. Researchers analyzed data from 3,655 participants with diabetes and no known atherosclerosis, finding a 31% lower rate of cardiovascular events in those receiving evolocumab compared to placebo over a median of 4.8 years.

“I think this study changes the paradigm,” stated Dr. Nicholas Marston, lead author of the study. “We don’t have to wait until someone has atherosclerosis to treat them intensively. We can—and should—be much more proactive.”

How Evolocumab Works: A Deep Dive

Evolocumab is an injectable monoclonal antibody that targets the PCSK9 protein. This protein hinders the liver’s ability to remove LDL-C (“bad” cholesterol) from the bloodstream. By blocking PCSK9, evolocumab boosts the number of LDL receptors in the liver, leading to a substantial reduction in LDL-C levels. In the VESALIUS-CV subgroup, LDL-C levels dropped to a median of 52 mg/dL with evolocumab, compared to 111 mg/dL with placebo after 48 weeks.

Did you know? Lowering LDL-C is a key strategy in preventing the buildup of plaque in arteries, a process known as atherosclerosis, which can lead to heart attack, and stroke.

The Implications for Guidelines and Future Practice

The findings from VESALIUS-CV align with recent guideline updates, such as the ACC/AHA Guideline on the Management of Dyslipidemia, which advocate for lower LDL-C targets earlier in life. The study supports the idea that more intensive LDL-C lowering treatment benefits patients at high cardiovascular risk, even in the absence of diagnosed atherosclerosis.

Although the study population was primarily older adults (median age 65) and predominantly White (93%), the results raise important questions about expanding access to PCSK9 inhibitors. Further research is needed to determine if similar benefits extend to younger patients and those with different cardiovascular risk profiles, including those without diabetes.

Potential Future Trends: Personalized Prevention

The success of VESALIUS-CV points towards a future of more personalized and proactive cardiovascular care. We may see:

  • Expanded Employ of PCSK9 Inhibitors: More widespread prescription of evolocumab and other PCSK9 inhibitors for high-risk individuals, even before the onset of significant atherosclerosis.
  • Genetic Screening: Increased use of genetic testing to identify individuals who are predisposed to high LDL-C levels and may benefit from early intervention.
  • Advanced Imaging Techniques: Development of more sensitive imaging techniques to detect early signs of atherosclerosis, allowing for earlier treatment initiation.
  • Combination Therapies: Exploration of combining PCSK9 inhibitors with other lipid-lowering therapies to achieve even greater reductions in LDL-C.

FAQ

Q: What is a PCSK9 inhibitor?
A: A PCSK9 inhibitor is a medication that lowers LDL (“bad”) cholesterol levels by blocking a protein called PCSK9.

Q: Who is eligible for evolocumab?
A: Traditionally, it was for those with existing heart disease. This study suggests it may be beneficial for high-risk individuals with diabetes and no known heart disease.

Q: What is atherosclerosis?
A: Atherosclerosis is the buildup of plaque in the arteries, which can lead to heart attack and stroke.

Q: What were the primary endpoints of the VESALIUS-CV trial?
A: The primary endpoints were a composite of death from coronary heart disease, heart attack, or ischemic stroke, and a composite of any of these three outcomes or a procedure to open blocked arteries.

Pro Tip: Talk to your doctor about your individual cardiovascular risk factors and whether intensive LDL-C lowering therapy is right for you.

This research offers a compelling argument for a more aggressive approach to heart disease prevention. As we continue to learn more about the role of LDL-C and the benefits of PCSK9 inhibition, we may be on the cusp of a new era in cardiovascular health.

Want to learn more? Explore additional articles on heart health and cholesterol management on our website.

March 30, 2026 0 comments
0 FacebookTwitterPinterestEmail
Newer Posts
Older Posts

Recent Posts

  • Latvia’s U18 Team Falls Short in Tournament Showdown Against Turkey

    July 3, 2026
  • Julio Rodríguez Sent to IL for Concussion

    July 3, 2026
  • Essential Pre-Travel Checklist: A Step-by-Step Guide to a Stress-Free Journey

    July 3, 2026
  • Prince Edward’s ‘Secret Romance’ with Ruthie Henshall

    July 3, 2026
  • Carry On King of Public Housing: Why One Hong Kong Man’s Uprooted Home Gets So Much Backlash

    July 3, 2026

Popular Posts

  • 1

    Maya Jama flaunts her taut midriff in a white crop top and denim jeans during holiday as she shares New York pub crawl story

    April 5, 2025
  • 2

    Saar-Unternehmen hoffen auf tiefgreifende Reformen

    March 26, 2025
  • 3

    Marta Daddato: vita e racconti tra YouTube e podcast

    April 7, 2025
  • 4

    Unlocking Success: Why the FPÖ Could Outperform Projections and Transform Austria’s Political Landscape

    April 26, 2025
  • 5

    Mecimapro Apologizes for DAY6 Concert Chaos: Understanding the Controversy

    May 6, 2025

Follow Me

Follow Me
  • Cookie Policy
  • CORRECTIONS POLICY
  • PRIVACY POLICY
  • TERMS OF SERVICE

© 2026 Newsy Today. All rights reserved.
For contact, advertising, copyright, issues email: [email protected]


Back To Top

For contact, advertising, copyright, issues email: [email protected]

Newsy Today
  • Business
  • Entertainment
  • Health
  • News
  • Sport
  • Tech
  • World